# Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Investigational Uses
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Notice.
**SUMMARY:**
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
**DATES:**
Fax written comments on the collection of information by October 24, 2011.
**ADDRESSES:**
To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or e-mailed to *[email protected].* All comments should be identified with the OMB control number 0910-0117. Also include the FDA docket number found in brackets in the heading of this document.
**FOR FURTHER INFORMATION CONTACT:**
Juanmanuel Vilela, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-7651, *[email protected].*
**SUPPLEMENTARY INFORMATION:**
In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.
**New Animal Drugs for Investigational Uses—21 CFR Part 511 (OMB Control Number 0910-0117)—Extension**
FDA has the authority under the Federal Food, Drug, and Cosmetic Act (FD&C Act) to approve new animal drugs. Section 512(j) of the FD&C Act (21 U.S.C. 360b(j)), authorizes FDA to issue regulations relating to the investigational use of new animal drugs. The regulations setting forth the conditions for investigational use of new animal drugs have been codified at part 511 (21 CFR part 511). If the new animal drug is only for tests in vitro or in laboratory research animals, the person distributing the new animal drug must maintain records showing the name and post office address of the expert or expert organization to whom it is shipped and the date, quantity, and batch or code mark of each shipment and delivery for a period of 2 years after such shipment or delivery. Before shipping a new animal drug for clinical investigations in animals, a sponsor must submit to FDA a Notice of Claimed Investigational Exemption (NCIE). The NCIE must contain, among other things, the following specific information: (1) Identity of the new animal drug, (2) labeling, (3) statement of compliance of any non-clinical laboratory studies with good laboratory practices, (4) name and address of each clinical investigator, (5) the approximate number of animals to be treated or amount of new animal drug(s) to be shipped, and (6) information regarding the use of edible tissues from investigational animals. Part 511 also requires that records be established and maintained to document the distribution and use of the investigational drug to assure that its use is safe, and that the distribution is controlled to prevent potential abuse. The agency uses these required records under its Bio-Research Monitoring Program to monitor the validity of the studies submitted to FDA to support new animal drug approval and to assure that proper use of the drug is maintained by the investigator.
Investigational new animal drugs are used primarily by drug industry firms, academic institutions, and the government. Investigators may include individuals from these entities as well as research firms and members of the medical profession. Respondents to this collection of information are the persons who use new animal drugs for purposes of an investigation.
In the *Federal Register* of June 28, 2011 (76 FR 37814), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.
FDA estimates the burden of this collection of information as follows:
| 21 CFR Part | Number of | Number of | Total annual | Average | Total hours |
| --- | --- | --- | --- | --- | --- |
| 511.1(b)(4) | 206 | 6.01 | 1,238 | 1 | 1,238 |
| 511.1(b)(5) | 206 | .34 | 70 | 8 | 560 |
| 511.1(b)(6) | 206 | .01 | 2 | 1 | 2 |
| 511.1(b)(8)(ii) | 206 | .07 | 15 | 2 | 30 |
| 511.1(b)(9) | 206 | .07 | 15 | 8 | 120 |
| Total | | | | | 1,950 |
| 21 CFR Part | Number of | Number of | Total annual records | Average | Total hours |
| --- | --- | --- | --- | --- | --- |
| 511.1(a)(3) | 206 | 2.30 | 473 | 1 | 473 |
| 511.1(b)(3) | 206 | 6.01 | 1,238 | 1 | 1,238 |
| 511.1(b)(7)(ii) | 206 | 6.01 | 1,238 | 3.5 | 4,333 |
| 511.1(b)(8)(i) | 206 | 6.01 | 1,238 | 3.5 | 4,333 |
| Total Burden Hours | | | | | 10,377 |
The estimate of the time required for reporting requirements, record preparation, and maintenance for this collection of information is based on agency communication with industry. Based on the number of sponsors subject to animal drug user fees, FDA estimates that there are 206 respondents. We use this estimate consistently throughout the table and calculate the “annual frequency per respondent” by dividing the total annual responses by number of respondents. Additional information needed to make a final calculation of the total burden hours ( *i.e.,* the number of respondents, the number of record keepers, the number of NCIEs received, *etc.* ) is derived from agency records.
Dated: September 19, 2011.
David Dorsey,
Acting Associate Commissioner for Policy and Planning.